乙型肝炎病毒相关肝细胞癌高危因素分析

摘要/Abstract

摘要： 肝细胞癌(hepatocellular carcinoma,HCC)作为全球关注的公共卫生问题,是原发性肝癌的主要病理分型。HCC病因复杂,乙型肝炎病毒(hepatitis B virus,HBV)感染为其首要病因,而HBV感染过程中,乙型肝炎e抗原(HBeAg)状态、乙型肝炎病毒脱氧核糖核酸(HBV-DNA)载量、HBV基因型、乙型肝炎表面抗原(HBsAg)水平及丙氨酸氨基转移酶(ALT)水平持续异常均可作为HCC的独立影响因素;同时男性性别、高龄、过量酒精摄入、高血糖水平等亦是HCC患病率增加的重要原因。为此,本文从以上角度探讨HCC发生的潜在高危因素,系统阐述HCC可能的发病机制,以期构建更为合理、敏感的疾病预警机制。

关键词: 肝细胞癌, 高危因素, 乙型肝炎病毒, 综述

邓霖霖, 石清兰, 韦华柱, 莫展进, 黄祖鸿. 乙型肝炎病毒相关肝细胞癌高危因素分析[J]. 肝脏, 2023, 28(5): 614-617.

参考文献

[1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] Chang Y, Lee JH. Optimal modalities for HCC surveillance in a high incidence region. Clin Liver Dis (Hoboken), 2021, 16(6): 236-239.
[3] Maucort-Boulch D, de Martel C, Franceschi S, et al. Fraction and incidence of liver cancer attribu-table to hepatitis B and C viruses worldwide. Int J Cancer, 2018, 142(12): 2471-2477.
[4] Konyn P, Ahmed A, Kim D. Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2021, 15(11): 1295-1307.
[5] Yang HI, Yuen MF, Chan HL, et al. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol, 2011, 12(6): 568-574.
[6] Fan C, Li M, Gan Y, et al. A simple AGED score for risk classification of primary liver cancer:development and validation with long-term prospective HBsAg-positive cohorts in Qidong, China. Gut, 2019, 68(5): 948-949.
[7] Tseng TC, Liu CJ, Yang HC, et al. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology, 2012, 142(5): 1140-1149.
[8] Wong VW, Janssen HL.Can we use HCC risk scores to individualize surveillance in chronic hepatitis B infection? J Hepatol, 2015, 63(3): 722-732.
[9] 李汨,聂青和,韩曼,等.HBV相关肝细胞癌的危险因素、早期筛查和预防策略.临床肝胆病杂志,2019,35(3):651-655.
[10] 杨健,沓世念,黄滔,等.慢性乙型肝炎患者抗病毒治疗对预防肝癌的研究结果分析.哈尔滨医药,2021,41(3):61-62.
[11] 安选,刘书宏,夏莉娜,等.HBeAg/HBeAb双阳性慢性乙型肝炎患者不同抗病毒方案疗效及临床转归分析.陆军军医大学学报,2022,44(2):162-167.
[12] Chen Y, Tian Z. HBV-induced immune imbalance in the development of HCC. Front Immunol, 2019, 10: 2048.
[13] 李韦杰,徐东平,韩佳琪,等.乙型肝炎自然进程中血清HBV RNA的动态变化及其与肝组织HBVcccDNA的关系.标记免疫分析与临床,2019,26(9):1445-1451+1460.
[14] Chu CM, Liaw YF. Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis, 2012, 54(1): 88-90.
[15] 刘甜,张伟,梁俊荣,等.慢性乙型肝炎患者病毒载量、PD-L1与肝纤维化及肝组织炎症活动度的相关性分析.解放军医药杂志,2021,33(4):40-44.
[16] 吴明山,刘振球,吴学福,等.HBV不同基因型致癌风险差异的系统综述和Meta分析.中华疾病控制杂志,2021,25(3):323-328.
[17] 吴湃,吴坤河,刘海燕,等.不同HBV基因型慢性乙型肝炎患者的血清HBV DNA、PreS1、HBeAg检测结果分析.分子诊断与治疗杂志,2019,11(6):495-498+507.
[18] Lau DTY, Ganova-Raeva L, Wang J, et al. Precore and basal core promoter hepatitis B virus (HBV) variants are present from a young age and differ across HBV genotypes. Hepatology, 2021, 73(5): 1637-1651.
[19] 周友乾,李翠.HBsAg定量在核苷(酸)类似物个体化抗HBV治疗中的应用价值.临床肝胆病杂志,2019,35(8):1821-1823.
[20] Wong GL, Chan HL, Tse YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. J Hepatol, 2018, 69(4): 793-802.
[21] 查旭东,刘文斌,曹广文.肝细胞癌发生及预后性别差异的相关危险因素.上海预防医学,2017,29(4):253-256.
[22] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis,staging and management of hepatocellular carcinoma:2018 practice guidance by the american association for the study of liver Diseases. Hepatology, 2018, 68(2): 723-750.
[23] Khan A, Shal B, Naveed M, et al. Matrine ameliorates anxiety and depression-like behaviour by targeting hyperammonemia-induced neuroinflammation and oxidative stress in CCl4 model of liver injury. Neurotoxicology, 2019, 72:38-50.
[24] 杨焘,宋厚盼,陈哲,等.基于SIRT1/AMPK信号通路探讨茵陈蒿汤治疗急性酒精性肝损伤的效应及机制.中药药理与临床,2022,38(1):36-40.
[25] 张利利,李玉芳,张驰,等.乙型肝炎肝硬化合并2型糖尿病发生原发性肝癌的风险研究.中华肝脏病杂志,2019(10):788-792.
[26] 王诗钰,李国超,陈柳,等.CD4+T细胞亚群与2型糖尿病发生发展的相关性研究.中国糖尿病杂志,2018,26(10):839-843.
[27] Kellenberger LD, Petrik J. Hyperglycemia promotes insulin-independent ovarian tumor growth. Gynecol Oncol, 2018, 149(2): 361-370.
[28] Cignarelli A, Genchi VA, Caruso I, et al. Diabetes and cancer: Pathophysiological fundamentals of a‘dangerous affair’. Diabetes Res Clin Pract, 2018, 143: 378-388.
[29] Chang WW, Lin RJ, Yu J, et al. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors. Breast Cancer Res, 2013, 15(3): R39.
[30] 宁欣.吸烟对大鼠免疫系统功能的影响.中国医药导报,2014,11(33):4-6+10.